Tarhini, A., Eroglu, Z., Zager, J. S., Gonzalez, R. J., Markowitz, J., Khushalani, N. I., Karapetyan, L., Brohl, A. S., Neves, R. I., Sarnaik, A., Perez, M. C., Chen, P., McCardle, T., Tsai, K. Y., Moreno, L. M., Bautista, J. M., Li, T., Wang, X., Messina, J., Sondak, V. K. (2026). A phase II study of neoadjuvant ipilimumab-nivolumab-relatlimab (INR) combination immunotherapy in high-risk resectable melanoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.9501